Get the Stockscreener App
4.05
5.15%
-0.22
Kezar Life Sciences Inc stock is traded at $4.05, with a volume of 67,095.
It is down -5.15% in the last 24 hours and down -7.95% over the past month.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
See More
Previous Close:
$4.27
Open:
$4.21
24h Volume:
67,095
Relative Volume:
1.39
Market Cap:
$31.20M
Revenue:
-
Net Income/Loss:
$-101.87M
P/E Ratio:
-2.8723
EPS:
-1.41
Net Cash Flow:
$-83.46M
1W Performance:
-6.03%
1M Performance:
-7.95%
6M Performance:
-37.50%
1Y Performance:
-36.12%
1-Day Range:
$4.00
$4.234
1-Week Range:
$4.00
$4.44
52-Week Range:
$3.6201
$9.18
Kezar Life Sciences Inc Stock (KZR) Company Profile
Name
Kezar Life Sciences Inc
Sector
Industry
Phone
650-822-5600
Address
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
4.05 | 31.20M | 0 | -101.87M | -83.46M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-16-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Wells Fargo | Outperform |
| Jul-16-18 | Initiated | William Blair | Outperform |
View All
Kezar Life Sciences Inc Stock (KZR) Latest News
Why Kezar Life Sciences Inc. stock attracts strong analyst attentionVolume Spike Detection for Early Breakouts - Newser
How Kezar Life Sciences Inc. stock performs during market volatilityFree Secure Capital Picks With Upside Potential - Newser
How Kezar Life Sciences Inc. stock reacts to Fed policy changesShort-Term AI-Based Stock Price Forecast - Newser
How does Kezar Life Sciences Inc. compare to its industry peersRetirement Planning Alerts That Work - jammulinksnews.com
What is Kezar Life Sciences Inc. company’s growth strategyBest Dividend Forecasts To Watch Now - jammulinksnews.com
Real time social sentiment graph for Kezar Life Sciences Inc.Free Scalable Portfolio Growth Suggestions - Newser
How to forecast Kezar Life Sciences Inc. trends using time seriesWeekly Growth Portfolio Performance Summary - Newser
Moving Average Trends for Kezar Life Sciences Inc. Stock: What They IndicateFree Early Entry Picks Before News Breakout - Newser
What is the risk reward ratio of investing in Kezar Life Sciences Inc. stockSmart Portfolio Recommendation For Beginners - jammulinksnews.com
What catalysts could drive Kezar Life Sciences Inc. stock higher in 2025AI Powered Strategy For Beginners - jammulinksnews.com
What makes Kezar Life Sciences Inc. stock price move sharplyFinancial News Entry Points Backed By Experts - jammulinksnews.com
Strategies to average down on Kezar Life Sciences Inc.Capital Growth Summary Over Five Years - Newser
Using flow based indicators on Kezar Life Sciences Inc.Trade Ideas Based on Fundamental Metrics - Newser
How to use a screener to detect Kezar Life Sciences Inc. breakoutsFree Pattern Breakout Entry Stock Forecast - Newser
Kezar Life Sciences Inc. Recovery Potential Based on Technical ToolsLow Risk Equity Screener With Results Shared - beatles.ru
How high can Kezar Life Sciences Inc. stock price go in 2025Free Stock Market Watch With Alerts - Newser
Kezar Life Sciences Inc. Stock Performance After Earnings: Historical InsightsHigh Yield Signals with Entry Timing - Newser
Published on: 2025-07-29 20:00:17 - metal.it
Why did KZR miss earnings forecasts in Q3? - AInvest
Watch for Trend Continuation in Kezar Life Sciences Inc. Next WeekReal-Time Trade Insights Spark Market Reactions - metal.it
How will KZR's Q4 earnings impact investors? - AInvest
Kezar Life Sciences Inc. Matches Institutional Buying FilterTrend Analysis for Safer Trades Gains Popularity - beatles.ru
Sentiment Tools Show Shift in Trader Mood on Kezar Life Sciences Inc.Pattern Breakout Entry Stock Forecast in Focus - metal.it
Published on: 2025-07-28 14:47:23 - metal.it
What is the dividend policy of Kezar Life Sciences Inc. stockAchieve exceptional returns with expert guidance - jammulinksnews.com
How Kezar Life Sciences Inc. stock reacts to Fed policy changes High Probability Trade Outcome Prediction - Newser
How volatile is Kezar Life Sciences Inc. stock compared to the marketMarket Forecast Entry Points For Smart Trading - jammulinksnews.com
Is Kezar Life Sciences Inc. stock overvalued or undervaluedAchieve breakthrough profits with expert advice - jammulinksnews.com
Does Kezar Life Sciences Inc. stock perform well during market downturnsAccelerated earnings growth - jammulinksnews.com
When is Kezar Life Sciences Inc. stock expected to show significant growthAchieve consistent profits with expert advice - jammulinksnews.com
How strong is Kezar Life Sciences Inc. company’s balance sheetRapid market gains - jammulinksnews.com
Kezar Life Sciences Inc Stock (KZR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kezar Life Sciences Inc Stock (KZR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schiller Mark C. | Chief Operating Officer |
Jul 02 '25 |
Sale |
4.28 |
561 |
2,401 |
2,739 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):